Use of statistical models for evaluating antibody response as a correlate of protection against varicella

Statistics in Medicine

Volumn 21, Issue 22, 2002, Pages 3411-3430

  Chan, Ivan S F ^a   Li, Shu ^a   Matthews, Holly ^a   Chan, Christina ^a   Vessey, Rupert ^a   Sadoff, Jerald ^a   Heyse, Joseph ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Accelerated failure time models; Bootstrap confidence intervals; gpELISA; Piecewise exponential regression; Prediction; Vaccine efficacy

Indexed keywords

CHICKENPOX VACCINE; GLYCOPROTEIN; VIRUS ANTIBODY;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHICKENPOX; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PARAMETRIC TEST; PREDICTION; REGRESSION ANALYSIS; STATISTICAL DISTRIBUTION; STATISTICAL MODEL; VACCINATION; VACCINE PRODUCTION;

ANTIBODIES, VIRAL; CHICKENPOX; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPESVIRUS 3, HUMAN; HUMANS; INFANT; MALE; MODELS, IMMUNOLOGICAL; MODELS, STATISTICAL; UNITED STATES; VACCINATION; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 0037202546     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1268     Document Type: Article

References (27)

1. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of H. influenzae type b. Journal of Infectious Disease 1984; 149:1034.
2. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA. Measles antibody: reevaluation of protective titres. Journal of Infectious Disease 1990; 162:1036-1042.
3. Wilson JN, Nokes DJ, Dimmock NJ. Analysis of the relationship between immunogenicity and immunity for viral subunit vaccines. Journal of Medical Virology 2001; 64(4):560-568.
4. Lachenbruch PA, Horne AD, Lynch CJ, Tiwari J, Ellenberg SS. Biologics. In Encyclopedia of Biopharmaceutical Statistics. Marcel Dekker: New York, 2000; 47-54.
5. Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, Connor KA, McLean AA, Hilleman MR, Buynak EB, Scolnick EM. Live attenuated varicella virus vaccine: efficacy trial in healthy children. New England Journal of Medicine 1984; 310:1409-1415.
6. Kuter BJ, Weibel RE, Guess HA, Mathews H, Morton DH, Neff BJ, Provost PH, Watson BA, Starr SE, Plotkin SA. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991; 9:643-647.
7. White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM, Capra A, Miller WJ, Krah DL, Provost PJ, Ellis RW, Calandra GB. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatric Infectious Disease Journal 1992; 11:19-23.
8. Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. Journal of Medical Virology 1990; 32:189-193.
9. Provost PJ, Krah DL, Kuter BJ, Morton DH, Schofield TL, Washmuth EH, White CJ, Miller WJ, Ellis RW. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine 1991; 9:111-116.
10. Vessey SJR, Chan CY, Kuter BJ, Kaplan KM, Waters M, Kutzler DP, Carfagno PA, Sadoff JC, Heyse JF, Mathews H, Li S, Chan ISF. Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. Journal of Pediatrics 2001; 139:297-304.
11. Krah DL, Cho I, Schofield T, Ellis RW. Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (Varivax®) in children and adults. Vaccine 1997; 15:61-64.
12. Watson B, Gupta R, Randall T, Starr S. Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine. The Journal of Infectious Disease 1994; 169: 197-199.
13. Lawless JF. Survival Models and Methods for Lifetime Data. Wiley: New York, 1982.
14. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Wiley: New York, 1980.
15. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26:404-413.
16. Johnson NL, Kotz S, Kemp AW. Univariate Discrete Distributions. 2nd edn. Wiley: New York, 1992; 170-172.
17. Rothman KJ, Greenland S. Modern Epidemiology. 2nd edn. Lippincott-Raven: Philadelphia, 1998; 234-236.
18. Guess HA, Broughton DD, Melton LJ III, Kurland LT. Population-based studies of varicella complications. Pediatrics 1986; 82:723-727.
19. Friedman M. Piecewise exponential models for survival data with covariates. Annals of Statistics 1982; 10: 101-113.
20. Allison PD. Survival Analysis using the SAS System-a Practical Guide. SAS Institute: Cary, North Carolina, 1995; chapter 4, 61-110.
21. Cox DR. Regression models and life-tables (with discussion). Journal of the Royal Statistical Society, Series B 1972, 34:187-220.
22. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Chapman & Hall: New York, 1993; 168-77.
23. Rubin DB. Multiple Imputation for Nonresponse in Surveys. Wiley: New York, 1987.
24. Li S, Chan ISF, Matthews H, Heyse JF, Chan CY, Kuter BJ, Kaplan KM, Vessey SJR, Sadoff JC. Childhood vaccination against varicella: inverse relationship between 6-week postvaccination varicella antibody response and likelihood of long-term breakthrough infection. Pediatric Infectious Disease Journal 2002; 21:337-342.
25. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Statistics in Medicine 1989; 8:431-440.
26. Freedman L, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic disease. Statistics in Medicine 1992; 11:167-178.
27. Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Statistics in Medicine 1997; 16:1515-1527.